Li Hongyu, Shen Ming, Wang Shihao
Department of Gastroenterology, The People's Hospital Of Changxing Country, Zhejiang, China.
Front Oncol. 2024 Feb 26;14:1327055. doi: 10.3389/fonc.2024.1327055. eCollection 2024.
Gastric cancer (GC) remains one of the most life-threatening disease worldwide with poor prognosis because of the absence of effective treatment and the delay in diagnosis. Due to the delay of diagnosis, a large proportion of GC patients are diagnosed as advanced GC, with extreme short lifespan. In the past few years, some pivotal progress and novel therapies was proposed, and conducted into clinical researches and practice. In this study, we summarized the development of several novel immunotherapy or targeted treatment modalities for advanced GC, including immune checkpoint inhibitors, anti-angiogenic therapy and cancer vaccines. Additionally, the advantage and potential weakness in each of these therapeutic methods are also listed. Finally, we discussed the promising research direction of advanced GC treatment, and the limitation in basic and clinical research of advanced GC, including the combination of immunotherapy and targeted therapy.
胃癌（GC）仍然是全球最具生命威胁的疾病之一，由于缺乏有效的治疗方法和诊断延迟，其预后较差。由于诊断延迟，很大一部分GC患者被诊断为晚期GC，寿命极短。在过去几年中，提出了一些关键进展和新疗法，并将其应用于临床研究和实践。在本研究中，我们总结了几种针对晚期GC的新型免疫疗法或靶向治疗方式的发展，包括免疫检查点抑制剂、抗血管生成疗法和癌症疫苗。此外，还列出了每种治疗方法的优点和潜在弱点。最后，我们讨论了晚期GC治疗的有前景的研究方向，以及晚期GC基础和临床研究中的局限性，包括免疫疗法和靶向疗法的联合应用。
